Status:
RECRUITING
Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial
Lead Sponsor:
Nebraska Methodist Health System
Conditions:
Postpartum Preeclampsia
Hypertension in Pregnancy
Eligibility:
FEMALE
19+ years
Phase:
PHASE4
Brief Summary
Randomized trial comparing risk of hospital readmission and hypertensive complications between patients managed on Labetalol compared to Nifedipine.
Detailed Description
Enrollment: Patients will be identified daily using an EMR screening tool. Those that meet inclusion criteria will then be approached by the investigators or research RN for enrollment. Patients cons...
Eligibility Criteria
Inclusion
- Any patient admitted for delivery by cesarean or vaginal delivery at 24 weeks gestation or greater with hypertension(HTN). Hypertension will be defined during the study as either a systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg on two occasions at least 4 hours apart. This definition is consistent with the ACOG definition for pregnancy related HTN. Following enrollment, treatment will be escalated at discretion of primary provider with the goal of normotension.
Exclusion
- History of moderate persistent asthma, coronary artery disease, heart failure, AV heart block, pulmonary edema
- Contraindication to either Nifedipine or Labetalol
- HR \<60 or \>110
- Native language other than English or Spanish
Key Trial Info
Start Date :
June 20 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT05309460
Start Date
June 20 2022
End Date
December 1 2024
Last Update
April 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nebraska Methodist Women's Hospital
Omaha, Nebraska, United States, 68022